Quick Answer
Transcode Therapeutics, Inc. reported Cash and Equivalents of $5.81 million for fiscal year 2024.
Transcode Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $5.81M | +110.0% |
| 2023 | $2.77M | -44.3% |
| 2022 | $4.97M | -76.1% |
| 2021 | $20.83M | +2415.2% |
| 2020 | $828.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.84M | +51.2% | -61.5% |
| June 30, 2025 | $7.37M | +119.8% | -36.3% |
| March 31, 2025 | $11.57M | +135.4% | +99.1% |
| December 31, 2024 | $5.81M | +110.0% | +209.8% |
| September 30, 2024 | $1.88M | -74.8% | -44.1% |
| June 30, 2024 | $3.35M | -6.1% | -31.7% |
| March 31, 2024 | $4.91M | +202.8% | +77.5% |
| December 31, 2023 | $2.77M | -44.3% | -62.9% |
- Transcode Therapeutics, Inc. showed an increase of +110.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, Transcode Therapeutics, Inc.’s cash and equivalents has grown by 601.8% (from $828.0 thousand to $5.81 million).
- The most recent figure is from Transcode Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: